Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 12/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118171 | 0.92 | GAA (0.43) | TLR4GAARCE1ARALDH1A1 | |
| SCHEMBL7116112 | 0.79 | PLA2G7 (0.40) | ARALDH1A1 | |
| SCHEMBL9135156 | 0.75 | GAA (0.49) | TLR4GAARCE1ALDH1A1IKBKB | |
| SCHEMBL7115607 | 0.75 | GAA (0.57) | TLR4GAARCE1ARALDH1A1 | |
| SCHEMBL7212332 | 0.73 | PTGES (0.44) | — | |
| SCHEMBL7198057 | 0.73 | TP53 (0.37) | GAAARALDH1A1LRRK2POLB | |
| SCHEMBL7129337 | 0.71 | TP53 (0.41) | ALDH1A1 | |
| SCHEMBL3277728 | 0.67 | ALDH1A1 (0.52) | GAAALDH1A1 | |
| SCHEMBL30940314 | 0.67 | ALDH1A1 (0.52) | GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL27778340 | 0.66 | ALDH1A1 (0.50) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | TLR4 2359/4885GAA 99/4885RCE1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.